Tags

Type your tag names separated by a space and hit enter

Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Vaccine. 2015 Jan 09; 33(3):451-8.V

Abstract

BACKGROUND

Since protective efficacy of the current typhoid vaccines-oral whole-cell Salmonella Typhi Ty21a and parenteral Vi-capsular polysaccharide preparation-is not optimal, and no vaccines are available against paratyphoid or non-typhoidal Salmonella (NTS) serotypes, new approaches deserve to be explored. The immunological mechanisms elicited by the two typhoid vaccines are mainly targeted against different structures. We studied whether these vaccines would enhance S. Typhi-specific immune response and cross-reactivity against other Salmonellae, if administered concomitantly.

MATERIALS AND METHODS

Volunteers were immunized simultaneously with Ty21a and Vi vaccines (Ty21a+Vi group) or with either of the two singly (Ty21a and Vi groups). All volunteers were investigated for circulating specific and cross-reactive plasmablasts, identified by ELISPOT as IgA, IgG or IgM antibody-secreting cells (ASC) reactive with S. Typhi, S. Paratyphi A/B/C, or selected NTS serotypes (S. Enteritidis, S. Typhimurium).

RESULTS

In the Ty21a+Vi group, no specific or cross-reactive plasmablasts were detected before vaccination. After vaccination, the number of S. Typhi-specific plasmablasts (878 ASC/10(6) PBMC, 95%CI 554-1201) proved higher than in the Ty21a (339 ASC/10(6) PBMC; p<0.001) and Vi (149 ASC/10(6) PBMC; p<0.001) groups. Likewise, cross-reactive responses in the Ty21a+Vi group were higher than in the Ty21a and Vi groups (Ty21a+Vi vs Ty21a: ASC against S. Paratyphi A/B, S. Enteritidis and S. Typhimurium p<0.05, against S. Paratyphi C p<0.01; Ty21a+Vi vs Vi: against S. Paratyphi C not significant, others p<0.0001). A gut-directed homing profile was seen among O antigen-specific and a systemic one among Vi antigen-specific plasmablasts.

CONCLUSIONS

Concomitant administration of Ty21a and Vi vaccines is well tolerated and induces an additive immune response to the two vaccines. Thus it enhances the magnitude of both typhoid-specific plasmablast responses and those cross-reacting with paratyphoid and most important NTS serotypes. The data encourage concomitant use of Ty21 and Vi vaccines for those at risk.

Authors+Show Affiliations

Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, POB 21, 00014 Helsinki, Finland; Department of Medicine, Division of Infectious Diseases, Helsinki University Hospital POB 348, 00029 Helsinki, Finland.Department of Medical Microbiology and Immunology, University of Turku, Kiinamyllynkatu 13, 20520 Turku, Finland.Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, POB 21, 00014 Helsinki, Finland.Karolinska Institutet, Department of Medicine/Solna, Unit for Infectious Diseases, Stockholm, Sweden; Centre for Clinical Research, Sörmland County Council, Eskilstuna, Sweden.Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, POB 21, 00014 Helsinki, Finland; Department of Medicine, Division of Infectious Diseases, Helsinki University Hospital POB 348, 00029 Helsinki, Finland; Department of Medicine, University of Helsinki, POB 20, 00014 Helsinki, Finland; Aava Travel Clinic, Medical Centre Aava, Helsinki, Finland. Electronic address: anu.kantele@hus.fi.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25433216

Citation

Pakkanen, Sari H., et al. "Specific and Cross-reactive Immune Response to Oral Salmonella Typhi Ty21a and Parenteral Vi Capsular Polysaccharide Typhoid Vaccines Administered Concomitantly." Vaccine, vol. 33, no. 3, 2015, pp. 451-8.
Pakkanen SH, Kantele JM, Savolainen LE, et al. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. Vaccine. 2015;33(3):451-8.
Pakkanen, S. H., Kantele, J. M., Savolainen, L. E., Rombo, L., & Kantele, A. (2015). Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. Vaccine, 33(3), 451-8. https://doi.org/10.1016/j.vaccine.2014.11.030
Pakkanen SH, et al. Specific and Cross-reactive Immune Response to Oral Salmonella Typhi Ty21a and Parenteral Vi Capsular Polysaccharide Typhoid Vaccines Administered Concomitantly. Vaccine. 2015 Jan 9;33(3):451-8. PubMed PMID: 25433216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. AU - Pakkanen,Sari H, AU - Kantele,Jussi M, AU - Savolainen,Laura E, AU - Rombo,Lars, AU - Kantele,Anu, Y1 - 2014/11/26/ PY - 2014/06/30/received PY - 2014/11/05/revised PY - 2014/11/17/accepted PY - 2014/11/30/entrez PY - 2014/11/30/pubmed PY - 2015/8/12/medline KW - Antibody-secreting cell KW - ClinicalTrials.gov NCT02121145 KW - Cross-reactive KW - ELISPOT KW - Homing KW - Non-typhoid Salmonella KW - Paratyphoid fever KW - S. Paratyphi KW - Salmonella Typhi KW - Salmonella Typhi Ty21a KW - Salmonella gastroenteritis KW - Typherix KW - Typhim Vi KW - Typhoid fever KW - Vi polysaccharide KW - Vivotif SP - 451 EP - 8 JF - Vaccine JO - Vaccine VL - 33 IS - 3 N2 - BACKGROUND: Since protective efficacy of the current typhoid vaccines-oral whole-cell Salmonella Typhi Ty21a and parenteral Vi-capsular polysaccharide preparation-is not optimal, and no vaccines are available against paratyphoid or non-typhoidal Salmonella (NTS) serotypes, new approaches deserve to be explored. The immunological mechanisms elicited by the two typhoid vaccines are mainly targeted against different structures. We studied whether these vaccines would enhance S. Typhi-specific immune response and cross-reactivity against other Salmonellae, if administered concomitantly. MATERIALS AND METHODS: Volunteers were immunized simultaneously with Ty21a and Vi vaccines (Ty21a+Vi group) or with either of the two singly (Ty21a and Vi groups). All volunteers were investigated for circulating specific and cross-reactive plasmablasts, identified by ELISPOT as IgA, IgG or IgM antibody-secreting cells (ASC) reactive with S. Typhi, S. Paratyphi A/B/C, or selected NTS serotypes (S. Enteritidis, S. Typhimurium). RESULTS: In the Ty21a+Vi group, no specific or cross-reactive plasmablasts were detected before vaccination. After vaccination, the number of S. Typhi-specific plasmablasts (878 ASC/10(6) PBMC, 95%CI 554-1201) proved higher than in the Ty21a (339 ASC/10(6) PBMC; p<0.001) and Vi (149 ASC/10(6) PBMC; p<0.001) groups. Likewise, cross-reactive responses in the Ty21a+Vi group were higher than in the Ty21a and Vi groups (Ty21a+Vi vs Ty21a: ASC against S. Paratyphi A/B, S. Enteritidis and S. Typhimurium p<0.05, against S. Paratyphi C p<0.01; Ty21a+Vi vs Vi: against S. Paratyphi C not significant, others p<0.0001). A gut-directed homing profile was seen among O antigen-specific and a systemic one among Vi antigen-specific plasmablasts. CONCLUSIONS: Concomitant administration of Ty21a and Vi vaccines is well tolerated and induces an additive immune response to the two vaccines. Thus it enhances the magnitude of both typhoid-specific plasmablast responses and those cross-reacting with paratyphoid and most important NTS serotypes. The data encourage concomitant use of Ty21 and Vi vaccines for those at risk. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/25433216/Specific_and_cross_reactive_immune_response_to_oral_Salmonella_Typhi_Ty21a_and_parenteral_Vi_capsular_polysaccharide_typhoid_vaccines_administered_concomitantly_ DB - PRIME DP - Unbound Medicine ER -